Nu Skin Q2 Revenue Plunges 17%, Books $78.9M Goodwill Impairment and $167.5M Tax Charge
NUS is trading near its 52-week low of $4.89 (6.5% below the low).
Summary
Nu Skin's Q2 revenue fell 17% to $320.1M, missing estimates, while a $78.9M goodwill impairment and a $167.5M deferred tax valuation allowance drove a GAAP loss of $5.14 per share. The company refinanced its debt and delayed its India market entry.
Key Events · Earnings and Guidance · NUS
-
Revenue Miss and Decline
Q2 revenue of $320.1M fell 17% YoY, missing the lone analyst estimate by $25M. All geographic segments declined, with South Korea down 25% and the Americas down 18%.
-
Goodwill Impairment
A $78.9M non-cash goodwill impairment was recorded in the Manufacturing reporting unit, triggered by a sustained decline in the company's stock price and reduced segment forecasts.
-
Deferred Tax Valuation Allowance
A $167.5M valuation allowance was established against U.S. deferred tax assets, reflecting management's assessment that it is more likely than not these assets will not be realized, driven by cumulative U.S. losses.
-
Debt Refinancing and Additional Draw
The company amended its credit agreement, reducing the term loan to $175M and adding a $75M revolver. Post-quarter, it drew an additional $30M on the revolver, bringing the total to $70M.
Analysis · NUS · Trade & Services
Nu Skin's second quarter results reveal a sharp deterioration in its core business, with revenue falling 17% to $320.1 million — missing the lone analyst estimate by $25 million. The company recorded a $78.9 million non-cash goodwill impairment in its manufacturing unit, reflecting the declining value of past acquisitions, and established a $167.5 million valuation allowance against U.S. deferred tax assets, signaling management's view that future U.S. profitability is unlikely to materialize soon. These charges drove a GAAP loss of $5.14 per share. The company also refinanced its debt, reducing its term loan to $175 million and adding a $75 million revolver, and drew an additional $30 million post-quarter. Strategic updates include a delay in the India market opening to the first half of 2027 and plans for an organizational realignment with $5 million in severance costs. The stock is trading near its 52-week low, and the combination of operational decline, asset impairments, and a shrinking balance sheet raises serious questions about the company's ability to stabilize its business.
At the time of this filing, NUS was trading at $4.57 on NYSE in the Trade & Services sector, with a market capitalization of approximately $250M. The 52-week trading range was $4.89 to $14.62. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.